Search

Your search keyword '"Whang, Young E."' showing total 331 results
Start Over Author "Whang, Young E."
331 results on '"Whang, Young E."'

1. Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Author

Rencsok, Emily M., Slopen, Natalie, Autio, Karen, Morgans, Alicia, McSwain, Lawrence, Barata, Pedro, Cheng, Heather H., Dreicer, Robert, Heath, Elisabeth, McKay, Rana R., Pomerantz, Mark, Rathkopf, Dana, Tagawa, Scott, Whang, Young E., Ragin, Camille, Odedina, Folakemi T., George, Daniel J., Kantoff, Philip W., Vinson, Jacob, Villanti, Paul, Haneuse, Sebastien, and Mucci, Lorelei A.

Published
2023
Full Text
View/download PDF

3. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.

Author

Szymaniak, Brittany M, Facchini, Lauren A, Giri, Veda N, Antonarakis, Emmanuel S, Beer, Tomasz M, Carlo, Maria I, Danila, Daniel C, Dhawan, Mallika, George, Daniel, Graff, Julie N, Gupta, Shilpa, Heath, Elisabeth, Higano, Celestia S, Liu, Glenn, Molina, Ana M, Paller, Channing J, Patnaik, Akash, Petrylak, Daniel P, Reichert, Zachery, Rettig, Matthew B, Ryan, Charles J, Taplin, Mary-Ellen, Vinson, Jake, Whang, Young E, Morgans, Alicia K, Cheng, Heather H, and McKay, Rana R

Subjects
Cancer, Aging, Urologic Diseases, Genetics, Prostate Cancer, Human Genome, Clinical Research, Good Health and Well Being, Genetic Testing, Germ Cells, Germ-Line Mutation, Humans, Male, Precision Medicine, Prostatic Neoplasms
Abstract

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.

Published
2020

4. Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

George, Daniel J., primary, Halabi, Susan, additional, Fleming, Mark T., additional, Heath, Elisabeth I., additional, Tutrone, Ronald, additional, Sutton, Linda, additional, Whang, Young E., additional, Lewis, Brian E., additional, Humeniuk, Michael Sandon, additional, Harrison, Michael Roger, additional, Kephart, Julie, additional, Hurrelbrink, Julia, additional, Rasmussen, Julia, additional, Shobe, Kellie, additional, Anand, Monika, additional, Reyes-Martinez, Marco, additional, Howard, Lauren, additional, Patierno, Steven R., additional, Freedman, Jennifer A, additional, and Armstrong, Andrew J., additional

Published
2024
Full Text
View/download PDF

5. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Author

Paller, Channing J, Antonarakis, Emmanuel S, Beer, Tomasz M, Borno, Hala T, Carlo, Maria I, George, Daniel J, Graff, Julie N, Gupta, Shilpa, Heath, Elisabeth I, Higano, Celestia S, McKay, Rana R, Morgans, Alicia K, Patnaik, Akash, Petrylak, Daniel P, Rettig, Matthew B, Ryan, Charles J, Taplin, Mary-Ellen, Whang, Young E, Vinson, Jacob, Cheng, Heather H, Giri, Veda N, and Group, PCCTC Germline Genetics Working

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Genetics, Clinical Research, Health Services, Aging, Urologic Diseases, Prostate Cancer, Good Health and Well Being, Genetic Counseling, Genetic Testing, Germ-Line Mutation, Health Workforce, Humans, Male, Medically Uninsured, Molecular Targeted Therapy, Practice Guidelines as Topic, Precision Medicine, Prostatic Neoplasms, Referral and Consultation, Surveys and Questionnaires, BRCA, DNA repair, Lynch, PARP inhibitors, Pembrolizumab, PCCTC Germline Genetics Working Group, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundGermline genetic testing increasingly identifies advanced prostate cancer (PCa) patients who are candidates for precision therapies. The Prostate Cancer Clinical Trials Consortium (PCCTC) established the Germline Genetics Working Group to provide guidance and resources to expand effective use of germline genetic testing.Materials and methodsA 14-item questionnaire was e-mailed to academic oncologists at 43 PCCTC sites to collect information on germline genetic testing patterns, including patients considered, choice of assays, barriers slowing adoption, and actions to overcome barriers.ResultsTwenty-six genitourinary oncologists from 19 institutions responded. Less than 40% (10 of 26) reported referring patients to a genetics department, whereas the remainder take personal responsibility for genetic testing and counseling; 16 (62%) consider testing all metastatic PCa patients, whereas 3 (12%) consider testing all patients with high-risk local disease; and 7 (27%) use multigene comprehensive pan-cancer panels, and 14 (54%) use smaller or targeted cancer gene panels. Barriers to widespread use are: (1) delayed or limited access to genetic counseling; (2) no insurance coverage; (3) lack of effective workflows; (4) insufficient educational materials; and (5) time and space constraints in busy clinics. The primary limitation was the

Published
2019

6. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

Author

Jathal, Maitreyee K, Steele, Thomas M, Siddiqui, Salma, Mooso, Benjamin A, D’Abronzo, Leandro S, Drake, Christiana M, Whang, Young E, and Ghosh, Paramita M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Breast Cancer, Urologic Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Cell Line, Tumor, Disease Models, Animal, ErbB Receptors, Humans, Lapatinib, Male, Mice, Mice, Inbred BALB C, Prostatic Neoplasms, Castration-Resistant, Protein Multimerization, Quinazolinones, Receptor, ErbB-2, Receptor, erbB-2, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundDespite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual EGFR/HER2 inhibitor lapatinib, failed in Phase II clinical trials. Hence, we investigated mechanisms of lapatinib resistance to determine whether alternate ErbB inhibitors can succeed.MethodsThe CWR22 human tumour xenograft and its CRPC subline 22Rv1 and sera from lapatinib-treated CRPC patients from a previously reported Phase II trial were used to study lapatinib resistance. Mechanistic studies were conducted in LNCaP, C4-2 and 22Rv1 cell lines.ResultsLapatinib increased intratumoral HER2 protein, which encouraged resistance to this treatment in mouse models. Sera from CRPC patients following lapatinib treatment demonstrated increased HER2 levels. Investigation of the mechanism of lapatinib-induced HER2 increase revealed that lapatinib promotes HER2 protein stability, leading to membrane localisation, EGFR/HER2 heterodimerisation and signalling, elevating cell viability. Knockdown of HER2 and ErbB3, but not EGFR, sensitised CRPC cells to lapatinib. At equimolar concentrations, the recently FDA-approved pan-ErbB inhibitor dacomitinib decreased HER2 protein stability, prevented ErbB membrane localisation (despite continued membrane integrity) and EGFR/HER2 heterodimerisation, thereby decreasing downstream signalling and increasing apoptosis.ConclusionsTargeting the EGFR axis using the irreversible pan-ErbB inhibitor dacomitinib is a viable therapeutic option for CRPC.

Published
2019

8. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

Author

Hussain, Maha, Daignault-Newton, Stephanie, Twardowski, Przemyslaw W, Albany, Costantine, Stein, Mark N, Kunju, Lakshmi P, Siddiqui, Javed, Wu, Yi-Mi, Robinson, Dan, Lonigro, Robert J, Cao, Xuhong, Tomlins, Scott A, Mehra, Rohit, Cooney, Kathleen A, Montgomery, Bruce, Antonarakis, Emmanuel S, Shevrin, Daniel H, Corn, Paul G, Whang, Young E, Smith, David C, Caram, Megan V, Knudsen, Karen E, Stadler, Walter M, Feng, Felix Y, and Chinnaiyan, Arul M

Subjects
Genetics, Prostate Cancer, Cancer, Urologic Diseases, Aged, Aged, 80 and over, Androstenes, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Biomarkers, Tumor, DNA Repair, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Poly(ADP-ribose) Polymerase Inhibitors, Prednisone, Prostatic Neoplasms, Castration-Resistant, Proto-Oncogene Proteins c-ets, Receptors, Androgen, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients and Methods Patients underwent metastatic site biopsy and were stratified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ETS fusions predicted response. Secondary objectives were: safety, measurable disease RR (mRR), progression-free survival (PFS), and molecular biomarker analysis. A total of 148 patients were randomly assigned to detect a 20% PSA RR improvement. Results A total of 148 patients with mCRPC were randomly assigned: arm A, n = 72; arm B, n = 76. There were no differences in PSA RR (63.9% v 72.4%; P = .27), mRR (45.0% v 52.2%; P = .51), or median PFS (10.1 v 11 months; P = .99). ETS fusions did not predict response. Exploratory analysis of tumor sequencing (80 patients) revealed: 41 patients (51%) were ETS positive, 20 (25%) had DNA-damage repair defect (DRD), 41 (51%) had AR amplification or copy gain, 34 (43%) had PTEN mutation, 33 (41%) had TP53 mutation, 39 (49%) had PIK3CA pathway activation, and 12 (15%) had WNT pathway alteration. Patients with DRD had significantly higher PSA RR (90% v 56.7%; P = .007) and mRR (87.5% v 38.6%; P = .001), PSA decline ≥ 90% (75% v 25%; P = .001), and longer median PFS (14.5 v 8.1 months; P = .025) versus those with wild-type tumors. Median PFS was longer in patients with normal PTEN (13.5 v 6.7 months; P = .02), TP53 (13.5 v 7.7 months; P = .01), and PIK3CA (13.8 v 8.3 months; P = .03) versus those with mutation or activation. In multivariable analysis adjusting for clinical covariates, DRD association with PFS remained significant. Conclusion Veliparib and ETS status did not affect response. Exploratory analysis identified a novel DRD association with mCRPC outcomes.

Published
2018

9. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

10. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

12. Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)

Author

Eulitt, Patrick J., Altun, Ersan, Sheikh, Arif, Wong, Terence Z., Woods, Michael E., Rose, Tracy L., Wallen, Eric M., Pruthi, Raj S., Smith, Angela B., Nielsen, Matthew E., Whang, Young E., Kim, William Y., Godley, Paul A., Basch, Ethan M., David, Grace U., Ramirez, Juanita, Deal, Allison M., Rathmell, W. Kimryn, Chen, Ronald C., Bjurlin, Marc A., Lin, Weili, Lee, Joseph K., and Milowsky, Matthew I.

Published
2020
Full Text
View/download PDF

13. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

16. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

17. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

18. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

19. TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

20. Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

21. BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Author

Hussain, Maha H. A., Kocherginsky, Masha, Agarwal, Neeraj, Adra, Nabil, Zhang, Jingsong, Paller, Channing Judith, Picus, Joel, Reichert, Zachery R, Szmulewitz, Russell Zelig, Tagawa, Scott T., Kuzel, Timothy, Bazzi, Latifa, Daignault-Newton, Stephanie, Whang, Young E., Dreicer, Robert, Stephenson, Ryan D., Rettig, Matthew, Shevrin, Daniel, Chinnaiyan, Arul, and Antonarakis, Emmanuel S.

Published
2024
Full Text
View/download PDF

34. Factors related to men’s experience with prostate cancer germline testing.

Author

Giri, Veda N., primary, Gross, Laura, additional, Hartman, Rebecca, additional, Leader, Amy, additional, Whang, Young E., additional, Couvillon, Anna, additional, Cheng, Heather H., additional, Paller, Channing Judith, additional, Loeb, Stacy, additional, Karsh, Lawrence Ivan, additional, Friedman, Sue J., additional, Beer, Tomasz M., additional, Sokolova, Alexandra, additional, and Keith, Scott W., additional

Published
2023
Full Text
View/download PDF

36. BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

Author

Hussain, Maha H. A., primary, Kocherginsky, Masha, additional, Agarwal, Neeraj, additional, Zhang, Jingsong, additional, Adra, Nabil, additional, Paller, Channing Judith, additional, Picus, Joel, additional, Reichert, Zachery R, additional, Szmulewitz, Russell Zelig, additional, Tagawa, Scott T., additional, Whang, Young E., additional, Dreicer, Robert, additional, Kuzel, Timothy, additional, Bazzi, Latifa, additional, Gerke, Travis A., additional, Daignault-Newton, Stephanie, additional, Chinnaiyan, Arul, additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

39. Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

Author

Hanson, Erik D., primary, Alzer, Mohamdod, additional, Carver, Jackson, additional, Stopforth, Cameron K., additional, Lucas, Alexander R., additional, Whang, Young E., additional, Milowsky, Matthew I., additional, Bartlett, David B., additional, Harrison, Michael R., additional, Bitting, Rhonda L., additional, Deal, Allison M., additional, Stoner, Lee, additional, Hackney, A. C., additional, and Battaglini, Claudio L., additional

Published
2022
Full Text
View/download PDF

40. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule

Author

Witek, Małgorzata A., Aufforth, Rachel D., Wang, Hong, Kamande, Joyce W., Jackson, Joshua M., Pullagurla, Swathi R., Hupert, Mateusz L., Usary, Jerry, Wysham, Weiya Z., Hilliard, Dawud, Montgomery, Stephanie, Bae-Jump, Victoria, Carey, Lisa A., Gehrig, Paola A., Milowsky, Matthew I., Perou, Charles M., Soper, John T., Whang, Young E., Yeh, Jen Jen, Martin, George, and Soper, Steven A.

Published
2017
Full Text
View/download PDF

41. Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

Author

Hanson, Erik D., Alzer, Mohamdod, Carver, Jackson, Stopforth, Cameron K., Lucas, Alexander R., Whang, Young E., Milowsky, Matthew I., Bartlett, David B., Harrison, Michael R., Bitting, Rhonda L., Deal, Allison M., Stoner, Lee, Hackney, A. C., and Battaglini, Claudio L.

Abstract

Background: Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. Purpose: To determine the feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC). Methods: mCRPC patients on androgen receptor signaling inhibitors (ARSI) were prescribed a 12-week, home-based exercise intervention using resistance bands and walking. Feasibility was assessed using recruitment, retention, adherence, and outcome capture. Physiological changes and patient reported outcomes were assessed before and after the intervention. Results: Of the 62 referrals, 47 were eligible with 22 men performing baseline testing (47% recruitment rate) and 16 completing the intervention (73% retention). Task completion was >86% for all physiological tests. Walking adherence was 80% and resistance training was 63%, the latter falling short of the study target (75%). Training increased thigh muscle cross-sectional area by 22%, time to exhaustion by 19% (both p< 0.05) and peak oxygen uptake by 6% (p= 0.057). Improvements in short physical performance battery scores and 400 m walk demonstrated moderate effect sizes that did not reach significance. Conclusions: Home-based exercise is feasible during ARSI treatment for mCRPC. Greater endurance capacity and localized hypertrophy appear as the primary improvements following training. These preliminary findings suggest home-based training may increase exercise accessibility, with important lessons that will inform subsequent trials investigating the efficacy of home-based exercise interventions during mCRPC.

Published
2023
Full Text
View/download PDF

44. Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Author

Kim, Stephanie I., primary, Szeto, Andy H., additional, Morgan, Katherine P., additional, Brower, Blaine, additional, Dunn, Mary W., additional, Khandani, Amir H., additional, Godley, Paul A., additional, Rose, Tracy L., additional, Basch, Ethan M., additional, Milowsky, Matthew I., additional, Whang, Young E, additional, and Crona, Daniel J, additional

Published
2021
Full Text
View/download PDF

46. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Author

Rose, Tracy L., primary, Harrison, Michael R., additional, Deal, Allison M., additional, Ramalingam, Sundhar, additional, Whang, Young E., additional, Brower, Blaine, additional, Dunn, Mary, additional, Osterman, Chelsea K., additional, Heiling, Hillary M., additional, Bjurlin, Marc A., additional, Smith, Angela B., additional, Nielsen, Matthew E., additional, Tan, Hung-Jui, additional, Wallen, Eric, additional, Woods, Michael E., additional, George, Daniel, additional, Zhang, Tian, additional, Drier, Anthony, additional, Kim, William Y., additional, and Milowsky, Matthew I., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results